FDA: Gout drug uloric increases risk of death

FDA: gout drug uloric increases risk of death

(HealthDay)—The gout medicine Uloric (febuxostat) carries a higher risk of death than allopurinol, according to the U.S. Food and Drug Administration.

The agency said its in-depth review of results from a safety clinical trial found that Uloric was associated with an increased risk of heart-related death and death from all causes.

Due to these findings, the FDA said it is updating Uloric prescribing information to require a Boxed Warning—the most prominent warning—and a new patient Medication Guide. The agency is also limiting the use of Uloric to certain patients who do not get effective results or suffer severe side effects when taking allopurinol. Health care professionals should counsel patients about the cardiovascular risk with Uloric and advise them to seek immediately if they experience symptoms such as , shortness of breath, rapid or irregular heartbeat, numbness or weakness on one side of the body, dizziness, trouble talking, and sudden severe headache.

The FDA approved Uloric in 2009 to treat adults with gout, a chronic disease that affects about 8.3 million U.S. adults. Only a few medicines are available to treat gout.


Explore further

FDA warns of rare stroke risk with MS drug

More information: More Information

Copyright © 2018 HealthDay. All rights reserved.

Citation: FDA: Gout drug uloric increases risk of death (2019, February 25) retrieved 20 October 2019 from https://medicalxpress.com/news/2019-02-fda-gout-drug-uloric-death.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
19 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more